STEM CELLS Translational Medicine: Breakthroughs have been made in the treatment of severe COVID-19 with interstitiotic stem cells

Based on the results published in STEM CELLS Translational Medicine, researchers at the Miller School of Medicine at the University of Miami in the United States have confirmed that interstitial stem cells infused with umbilical cord sources can reduce the risk of death and reduce recovery time in patients with severe COVID-19.
the trial recruited 24 patients with severe acute respiratory distress syndrome who received a total of two interstitational stem cell or placebo infusions every other day.
is a double-blind study," commented Dr. Camille Ricordi, director of the Diabetes Institute (DRI) and Cell Transplant Center at the Miller School of Medicine at the University of Miami.
200 million cells were infused twice in three days for each subject in the treatment group.
results show that interstate stem cell therapy is safe and there are no serious adverse events associated with infusion".
30-day survival rate was 91 percent for patients in the stem cell therapy group, compared with 42 percent for the control group.
patients under the age of 85, the 30-day survival rate of patients in the interstumogenic stem cell therapy group was 100%.
and colleagues also found that patients in the treatment group recovered faster.
more than half of the patients who received interstity stem cell infusion therapy recovered within two weeks of the last treatment and returned home from the hospital.
30 days, more than 80 percent of patients in the treatment group recovered, compared with less than 37 percent in the control group.